BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Godwin P, Baird AM, Heavey S, Barr MP, O'Byrne KJ, Gately K. Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol 2013;3:120. [PMID: 23720710 DOI: 10.3389/fonc.2013.00120] [Cited by in Crossref: 134] [Cited by in F6Publishing: 136] [Article Influence: 16.8] [Reference Citation Analysis]
Number Citing Articles
1 Yeldag G, Rice A, Del Río Hernández A. Chemoresistance and the Self-Maintaining Tumor Microenvironment. Cancers (Basel) 2018;10:E471. [PMID: 30487436 DOI: 10.3390/cancers10120471] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 19.3] [Reference Citation Analysis]
2 Lan M, Lu W, Zou T, Li L, Liu F, Cai T, Cai Y. Role of inflammatory microenvironment: potential implications for improved breast cancer nano-targeted therapy. Cell Mol Life Sci 2021;78:2105-29. [PMID: 33386887 DOI: 10.1007/s00018-020-03696-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Valletti A, Marzano F, Pesole G, Sbisà E, Tullo A. Targeting Chemoresistant Tumors: Could TRIM Proteins-p53 Axis Be a Possible Answer? Int J Mol Sci 2019;20:E1776. [PMID: 30974870 DOI: 10.3390/ijms20071776] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
4 Aktepe OH, Şahin TK, Güner G, Arik Z, Yalçin Ş. Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factor- kappa B (NF-κB) pathway. Turk J Med Sci 2021;51:368-74. [PMID: 32718121 DOI: 10.3906/sag-2005-413] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
5 Seubwai W, Wongkham C, Puapairoj A, Khuntikeo N, Pugkhem A, Hahnvajanawong C, Chaiyagool J, Umezawa K, Okada S, Wongkham S. Aberrant expression of NF-κB in liver fluke associated cholangiocarcinoma: implications for targeted therapy. PLoS One 2014;9:e106056. [PMID: 25170898 DOI: 10.1371/journal.pone.0106056] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
6 Jo E, Jang HJ, Yang KE, Jang MS, Huh YH, Yoo HS, Park JS, Jang IS, Park SJ. Cordyceps militaris induces apoptosis in ovarian cancer cells through TNF-α/TNFR1-mediated inhibition of NF-κB phosphorylation. BMC Complement Med Ther 2020;20:1. [PMID: 32020859 DOI: 10.1186/s12906-019-2780-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 21.0] [Reference Citation Analysis]
7 Huang P, Ouyang DJ, Chang S, Li MY, Li L, Li QY, Zeng R, Zou QY, Su J, Zhao P, Pei L, Yi WJ. Chemotherapy-driven increases in the CDKN1A/PTN/PTPRZ1 axis promote chemoresistance by activating the NF-κB pathway in breast cancer cells. Cell Commun Signal 2018;16:92. [PMID: 30497491 DOI: 10.1186/s12964-018-0304-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
8 Pignochino Y, Capozzi F, D'Ambrosio L, Dell'Aglio C, Basiricò M, Canta M, Lorenzato A, Vignolo Lutati F, Aliberti S, Palesandro E, Boccone P, Galizia D, Miano S, Chiabotto G, Napione L, Gammaitoni L, Sangiolo D, Benassi MS, Pasini B, Chiorino G, Aglietta M, Grignani G. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models. Mol Cancer 2017;16:86. [PMID: 28454547 DOI: 10.1186/s12943-017-0652-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 8.5] [Reference Citation Analysis]
9 Breyer MD, Susztak K. The next generation of therapeutics for chronic kidney disease. Nat Rev Drug Discov 2016;15:568-88. [PMID: 27230798 DOI: 10.1038/nrd.2016.67] [Cited by in Crossref: 122] [Cited by in F6Publishing: 116] [Article Influence: 24.4] [Reference Citation Analysis]
10 Park YH. The nuclear factor-kappa B pathway and response to treatment in breast cancer. Pharmacogenomics 2017;18:1697-709. [PMID: 29182047 DOI: 10.2217/pgs-2017-0044] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
11 Scheurer MJJ, Brands RC, El-Mesery M, Hartmann S, Müller-Richter UDA, Kübler AC, Seher A. The Selection of NFκB Inhibitors to Block Inflammation and Induce Sensitisation to FasL-Induced Apoptosis in HNSCC Cell Lines Is Critical for Their Use as a Prospective Cancer Therapy. Int J Mol Sci 2019;20:E1306. [PMID: 30875877 DOI: 10.3390/ijms20061306] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
12 Zhu H, Zou X, Lin S, Hu X, Gao J. Effects of naringin on reversing cisplatin resistance and the Wnt/β-catenin pathway in human ovarian cancer SKOV3/CDDP cells. J Int Med Res 2020;48:300060519887869. [PMID: 33086930 DOI: 10.1177/0300060519887869] [Reference Citation Analysis]
13 Khurana N, Dodhiawala PB, Bulle A, Lim KH. Deciphering the Role of Innate Immune NF-ĸB Pathway in Pancreatic Cancer. Cancers (Basel) 2020;12:E2675. [PMID: 32961746 DOI: 10.3390/cancers12092675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Aversa I, Chirillo R, Chiarella E, Zolea F, Di Sanzo M, Biamonte F, Palmieri C, Costanzo F. Chemoresistance in H-Ferritin Silenced Cells: The Role of NF-κB. Int J Mol Sci 2018;19:E2969. [PMID: 30274235 DOI: 10.3390/ijms19102969] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
15 Huehnchen P, Muenzfeld H, Boehmerle W, Endres M. Blockade of IL-6 signaling prevents paclitaxel-induced neuropathy in C57Bl/6 mice. Cell Death Dis 2020;11:45. [PMID: 31969555 DOI: 10.1038/s41419-020-2239-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
16 Ma X, Yan L, Zhu Q, Shao F. Puerarin attenuates cisplatin-induced rat nephrotoxicity: The involvement of TLR4/NF-κB signaling pathway. PLoS One 2017;12:e0171612. [PMID: 28182789 DOI: 10.1371/journal.pone.0171612] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
17 Chi RA, van der Watt P, Wei W, Birrer MJ, Leaner VD. Inhibition of Kpnβ1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer. BMC Cancer 2021;21:106. [PMID: 33530952 DOI: 10.1186/s12885-021-07819-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Trochopoulos AGX, Zaharieva MM, Marinova MH, Yoncheva K, Tibi IP, Berger MR, Konstantinov SM. Antineoplastic effect of a novel nanosized curcumin on cutaneous T cell lymphoma. Oncol Lett 2020;20:304. [PMID: 33093913 DOI: 10.3892/ol.2020.12167] [Reference Citation Analysis]
19 Velloso FJ, Bianco AF, Farias JO, Torres NE, Ferruzo PY, Anschau V, Jesus-Ferreira HC, Chang TH, Sogayar MC, Zerbini LF, Correa RG. The crossroads of breast cancer progression: insights into the modulation of major signaling pathways. Onco Targets Ther 2017;10:5491-524. [PMID: 29200866 DOI: 10.2147/OTT.S142154] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
20 Chen F, Qin X, Xu G, Gou S, Jin X. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways. Biochem Pharmacol 2017;135:50-68. [PMID: 28288821 DOI: 10.1016/j.bcp.2017.03.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
21 Riedlinger T, Haas J, Busch J, van de Sluis B, Kracht M, Schmitz ML. The Direct and Indirect Roles of NF-κB in Cancer: Lessons from Oncogenic Fusion Proteins and Knock-in Mice. Biomedicines 2018;6:E36. [PMID: 29562713 DOI: 10.3390/biomedicines6010036] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
22 Uematsu A, Kido K, Manabe E, Takeda H, Takahashi H, Hayashi M, Imai Y, Sawasaki T. DANFIN functions as an inhibitor of transcription factor NF-κB and potentiates the antitumor effect of bortezomib in multiple myeloma. Biochem Biophys Res Commun 2018;495:2289-95. [PMID: 29284118 DOI: 10.1016/j.bbrc.2017.12.142] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
23 Kozak J, Forma A, Czeczelewski M, Kozyra P, Sitarz E, Radzikowska-Büchner E, Sitarz M, Baj J. Inhibition or Reversal of the Epithelial-Mesenchymal Transition in Gastric Cancer: Pharmacological Approaches. Int J Mol Sci 2020;22:E277. [PMID: 33383973 DOI: 10.3390/ijms22010277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
24 Camorani S, Cerchia L, Fedele M, Erba E, D'Incalci M, Crescenzi E. Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-κB. Oncotarget 2018;9:19929-44. [PMID: 29731994 DOI: 10.18632/oncotarget.24961] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
25 Ghoneum A, Almousa S, Warren B, Abdulfattah AY, Shu J, Abouelfadl H, Gonzalez D, Livingston C, Said N. Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer. Semin Cancer Biol 2021:S1044-579X(21)00003-1. [PMID: 33476723 DOI: 10.1016/j.semcancer.2020.12.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Wang J, Zhang Z, Che Y, Yuan Z, Lu Z, Li Y, Wan J, Sun H, Chen Z, Pu J, He J. Rabdocoestin B exhibits antitumor activity by inducing G2/M phase arrest and apoptosis in esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 2018;81:469-81. [PMID: 29308536 DOI: 10.1007/s00280-017-3507-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Vennin C, Mélénec P, Rouet R, Nobis M, Cazet AS, Murphy KJ, Herrmann D, Reed DA, Lucas MC, Warren SC, Elgundi Z, Pinese M, Kalna G, Roden D, Samuel M, Zaratzian A, Grey ST, Da Silva A, Leung W, Mathivanan S, Wang Y, Braithwaite AW, Christ D, Benda A, Parkin A, Phillips PA, Whitelock JM, Gill AJ, Sansom OJ, Croucher DR, Parker BL, Pajic M, Morton JP, Cox TR, Timpson P; Australian Pancreatic Genome Initiative (APGI). CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nat Commun 2019;10:3637. [PMID: 31406163 DOI: 10.1038/s41467-019-10968-6] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 35.5] [Reference Citation Analysis]
28 Dimitrakopoulos FD, Kottorou AE, Antonacopoulou AG, Panagopoulos N, Scopa C, Kalofonou M, Dougenis D, Koutras A, Makatsoris T, Tzelepi V, Kalofonos HP. Expression of Immune System-Related Membrane Receptors CD40, RANK, BAFFR and LTβR is Associated with Clinical Outcome of Operated Non-Small-Cell Lung Cancer Patients. J Clin Med 2019;8:E741. [PMID: 31137630 DOI: 10.3390/jcm8050741] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
29 Santos JMO, Moreira‐pais A, Neto T, Peixoto da Silva S, Oliveira PA, Ferreira R, Mendes J, Bastos MMSM, Lopes C, Casaca F, Silva S, Sweeney C, Medeiros R, Gil da Costa RM. Dimethylaminoparthenolide reduces the incidence of dysplasia and ameliorates a wasting syndrome in HPV16‐transgenic mice. Drug Dev Res 2019;80:824-30. [DOI: 10.1002/ddr.21565] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
30 Fouani L, Kovacevic Z, Richardson DR. Targeting Oncogenic Nuclear Factor Kappa B Signaling with Redox-Active Agents for Cancer Treatment. Antioxidants & Redox Signaling 2019;30:1096-123. [DOI: 10.1089/ars.2017.7387] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
31 Sadri Nahand J, Rabiei N, Fathazam R, Taghizadieh M, Ebrahimi MS, Mahjoubin-Tehran M, Bannazadeh Baghi H, Khatami A, Abbasi-Kolli M, Mirzaei HR, Rahimian N, Darvish M, Mirzaei H. Oncogenic viruses and chemoresistance: What do we know? Pharmacol Res 2021;170:105730. [PMID: 34119621 DOI: 10.1016/j.phrs.2021.105730] [Reference Citation Analysis]
32 Anwer F, Gee KM, Iftikhar A, Baig M, Russ AD, Saeed S, Zar MA, Razzaq F, Carew J, Nawrocki S, Al-Kateb H, Cavalcante Parr NN, McBride A, Valent J, Samaras C. Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma. Clin Lymphoma Myeloma Leuk 2019;19:397-405. [PMID: 31036508 DOI: 10.1016/j.clml.2019.03.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
33 Wang YJ, Zhao HD, Zhu CF, Li J, Xie HJ, Chen YX. Tuberostemonine reverses multidrug resistance in chronic myelogenous leukemia cells K562/ADR. J Cancer 2017;8:1103-12. [PMID: 28529625 DOI: 10.7150/jca.17688] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
34 Comen EA, Bowman RL, Kleppe M. Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment. Front Cell Dev Biol 2018;6:56. [PMID: 29946544 DOI: 10.3389/fcell.2018.00056] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
35 Barrera G, Cucci MA, Grattarola M, Dianzani C, Muzio G, Pizzimenti S. Control of Oxidative Stress in Cancer Chemoresistance: Spotlight on Nrf2 Role. Antioxidants (Basel) 2021;10:510. [PMID: 33805928 DOI: 10.3390/antiox10040510] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Park M, Yoon HJ, Kang MC, Kwon J, Lee HW. PTK7 regulates radioresistance through nuclear factor-kappa B in esophageal squamous cell carcinoma. Tumour Biol 2016;37:14217-24. [PMID: 27557627 DOI: 10.1007/s13277-016-5288-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
37 Zhang S, Lin X. CARMA3: Scaffold Protein Involved in NF-κB Signaling. Front Immunol 2019;10:176. [PMID: 30814996 DOI: 10.3389/fimmu.2019.00176] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
38 Coker-Gurkan A, Bulut D, Genc R, Arisan ED, Obakan-Yerlikaya P, Palavan-Unsal N. Curcumin prevented human autocrine growth hormone (GH) signaling mediated NF-κB activation and miR-183-96-182 cluster stimulated epithelial mesenchymal transition in T47D breast cancer cells. Mol Biol Rep 2019;46:355-69. [PMID: 30467667 DOI: 10.1007/s11033-018-4479-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
39 Lee N, Nikfarjam M, He H. Functions of the CXC ligand family in the pancreatic tumor microenvironment. Pancreatology 2018;18:705-16. [DOI: 10.1016/j.pan.2018.07.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
40 Miow QH, Tan TZ, Ye J, Lau JA, Yokomizo T, Thiery JP, Mori S. Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene 2015;34:1899-907. [PMID: 24858042 DOI: 10.1038/onc.2014.136] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 10.0] [Reference Citation Analysis]
41 Zhai Z, Vaddi PK, Samson JM, Takegami T, Fujita M. NLRP1 Functions Downstream of the MAPK/ERK Signaling via ATF4 and Contributes to Acquired Targeted Therapy Resistance in Human Metastatic Melanoma. Pharmaceuticals (Basel) 2020;14:23. [PMID: 33396632 DOI: 10.3390/ph14010023] [Reference Citation Analysis]
42 Miao L, Guo S, Lin CM, Liu Q, Huang L. Nanoformulations for combination or cascade anticancer therapy. Adv Drug Deliv Rev 2017;115:3-22. [PMID: 28624477 DOI: 10.1016/j.addr.2017.06.003] [Cited by in Crossref: 99] [Cited by in F6Publishing: 86] [Article Influence: 24.8] [Reference Citation Analysis]
43 Lampi MC, Reinhart-king CA. Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials. Sci Transl Med 2018;10:eaao0475. [DOI: 10.1126/scitranslmed.aao0475] [Cited by in Crossref: 181] [Cited by in F6Publishing: 157] [Article Influence: 60.3] [Reference Citation Analysis]
44 de Oliveira VA, da Motta LL, De Bastiani MA, Lopes FM, Müller CB, Gabiatti BP, França FS, Castro MA, Klamt F. In vitro evaluation of antitumoral efficacy of catalase in combination with traditional chemotherapeutic drugs against human lung adenocarcinoma cells. Tumour Biol 2016;37:10775-84. [PMID: 26873489 DOI: 10.1007/s13277-016-4973-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
45 Mayo V, Bowles AC, Wubker LE, Ortiz I, Cordoves AM, Cote RJ, Correa D, Agarwal A. Human-derived osteoblast-like cells and pericyte-like cells induce distinct metastatic phenotypes in primary breast cancer cells. Exp Biol Med (Maywood) 2021;246:971-85. [PMID: 33210551 DOI: 10.1177/1535370220971599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Moreira H, Szyjka A, Gąsiorowski K. Chemopreventive activity of celastrol in drug-resistant human colon carcinoma cell cultures. Oncotarget 2018;9:21211-23. [PMID: 29765532 DOI: 10.18632/oncotarget.25014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
47 Rada M, Nallanthighal S, Cha J, Ryan K, Sage J, Eldred C, Ullo M, Orsulic S, Cheon DJ. Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer. Oncogene 2018;37:4809-20. [PMID: 29769618 DOI: 10.1038/s41388-018-0297-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
48 Prescott JA, Cook SJ. Targeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ Inhibitors. Cells 2018;7:E115. [PMID: 30142927 DOI: 10.3390/cells7090115] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 15.0] [Reference Citation Analysis]
49 Luan X, Rahme K, Cong Z, Wang L, Zou Y, He Y, Yang H, Holmes JD, O'Driscoll CM, Guo J. Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice. Eur J Pharm Biopharm 2019;137:56-67. [PMID: 30779980 DOI: 10.1016/j.ejpb.2019.02.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
50 Zaytseva M, Papusha L, Novichkova G, Druy A. Molecular Stratification of Childhood Ependymomas as a Basis for Personalized Diagnostics and Treatment. Cancers (Basel) 2021;13:4954. [PMID: 34638438 DOI: 10.3390/cancers13194954] [Reference Citation Analysis]
51 Tarhouni-Jabberi S, Zakraoui O, Ioannou E, Riahi-Chebbi I, Haoues M, Roussis V, Kharrat R, Essafi-Benkhadir K. Mertensene, a Halogenated Monoterpene, Induces G2/M Cell Cycle Arrest and Caspase Dependent Apoptosis of Human Colon Adenocarcinoma HT29 Cell Line through the Modulation of ERK-1/-2, AKT and NF-κB Signaling. Mar Drugs 2017;15:E221. [PMID: 28726723 DOI: 10.3390/md15070221] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
52 Day EK, Sosale NG, Xiao A, Zhong Q, Purow B, Lazzara MJ. Glioblastoma Cell Resistance to EGFR and MET Inhibition Can Be Overcome via Blockade of FGFR-SPRY2 Bypass Signaling. Cell Rep 2020;30:3383-3396.e7. [PMID: 32160544 DOI: 10.1016/j.celrep.2020.02.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
53 Shahbazi S, Kaur J, Singh S, Achary KG, Wani S, Jema S, Akhtar J, Sobti RC. Impact of novel N-aryl piperamide NO donors on NF-κB translocation in neuroinflammation: rational drug-designing synthesis and biological evaluation. Innate Immun 2018;24:24-39. [PMID: 29145791 DOI: 10.1177/1753425917740727] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
54 Hu L, Chen D, Wang Y, Qin Y, Huang P, Yu L, Liao J, Hua X. Smilax china L. rhizome extract inhibits nuclear factor-κB and induces apoptosis in ovarian cancer cells. Chin J Integr Med 2015;21:907-15. [DOI: 10.1007/s11655-014-1788-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
55 Heavey S, Godwin P, Baird AM, Barr MP, Umezawa K, Cuffe S, Finn SP, O'Byrne KJ, Gately K. Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC. Cancer Biol Ther 2014;15:1367-77. [PMID: 25025901 DOI: 10.4161/cbt.29841] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
56 Liu S, Lai W, Shi Y, Liu N, Ouyang L, Zhang Z, Chen L, Wang X, Qian B, Xiao D, Yan Q, Cao Y, Liu S, Tao Y. Annotation and cluster analysis of long noncoding RNA linked to male sex and estrogen in cancers. NPJ Precis Oncol 2020;4:5. [PMID: 33654193 DOI: 10.1038/s41698-020-0110-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
57 Lodhi N, Tun M, Nagpal P, Inamdar AA, Ayoub NM, Siyam N, Oton-Gonzalez L, Gerona A, Morris D, Sandhu R, Suh KS. Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine. Oncotarget 2020;11:4045-73. [PMID: 33216822 DOI: 10.18632/oncotarget.27785] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
58 Sullivan GP, O'Connor H, Henry CM, Davidovich P, Clancy DM, Albert ML, Cullen SP, Martin SJ. TRAIL Receptors Serve as Stress-Associated Molecular Patterns to Promote ER-Stress-Induced Inflammation. Dev Cell 2020;52:714-730.e5. [PMID: 32109381 DOI: 10.1016/j.devcel.2020.01.031] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
59 Shivange G, Urbanek K, Przanowski P, Perry JSA, Jones J, Haggart R, Kostka C, Patki T, Stelow E, Petrova Y, Llaneza D, Mayo M, Ravichandran KS, Landen CN, Bhatnagar S, Tushir-Singh J. A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer. Cancer Cell 2018;34:331-345.e11. [PMID: 30107179 DOI: 10.1016/j.ccell.2018.07.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
60 Feng X, Zhang Q, Xia S, Xia B, Zhang Y, Deng X, Su W, Huang J. MTA1 overexpression induces cisplatin resistance in nasopharyngeal carcinoma by promoting cancer stem cells properties. Mol Cells 2014;37:699-704. [PMID: 25245523 DOI: 10.14348/molcells.2014.0029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
61 Suryavanshi SV, Kulkarni YA. NF-κβ: A Potential Target in the Management of Vascular Complications of Diabetes. Front Pharmacol 2017;8:798. [PMID: 29163178 DOI: 10.3389/fphar.2017.00798] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 24.8] [Reference Citation Analysis]
62 Islam SS, Al-Sharif I, Sultan A, Al-Mazrou A, Remmal A, Aboussekhra A. Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-κB signaling pathway. Mol Carcinog 2018;57:333-46. [PMID: 29073729 DOI: 10.1002/mc.22758] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
63 Michel J, Nolin F, Wortham L, Lalun N, Tchelidze P, Banchet V, Terryn C, Ploton D. Various Nucleolar Stress Inducers Result in Highly Distinct Changes in Water, Dry Mass and Elemental Content in Cancerous Cell Compartments: Investigation Using a Nano-Analytical Approach. Nanotheranostics 2019;3:179-95. [PMID: 31183313 DOI: 10.7150/ntno.31878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Ahmed S, Khan H, Aschner M, Mirzae H, Küpeli Akkol E, Capasso R. Anticancer Potential of Furanocoumarins: Mechanistic and Therapeutic Aspects. Int J Mol Sci 2020;21:E5622. [PMID: 32781533 DOI: 10.3390/ijms21165622] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
65 Mol M, Kosey D, Boppana R, Singh S. Transcription Factor Target Gene Network governs the Logical Abstraction Analysis of the Synthetic Circuit in Leishmaniasis. Sci Rep 2018;8:3464. [PMID: 29472639 DOI: 10.1038/s41598-018-21840-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
66 Wirth M, Schick M, Keller U, Krönke J. Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy. Cancers (Basel) 2020;12:E3764. [PMID: 33327527 DOI: 10.3390/cancers12123764] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
67 Darwish NHE, Sudha T, Godugu K, Bharali DJ, Elbaz O, El-Ghaffar HAA, Azmy E, Anber N, Mousa SA. Novel Targeted Nano-Parthenolide Molecule against NF-kB in Acute Myeloid Leukemia. Molecules 2019;24:E2103. [PMID: 31163672 DOI: 10.3390/molecules24112103] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
68 Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol 2018;18:309-24. [DOI: 10.1038/nri.2017.142] [Cited by in Crossref: 718] [Cited by in F6Publishing: 717] [Article Influence: 239.3] [Reference Citation Analysis]
69 Worzfeld T, Pogge von Strandmann E, Huber M, Adhikary T, Wagner U, Reinartz S, Müller R. The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. Front Oncol 2017;7:24. [PMID: 28275576 DOI: 10.3389/fonc.2017.00024] [Cited by in Crossref: 95] [Cited by in F6Publishing: 94] [Article Influence: 23.8] [Reference Citation Analysis]
70 Lam T, Aguirre‐ghiso JA, Geller MA, Aksan A, Azarin SM. Immobilization rapidly selects for chemoresistant ovarian cancer cells with enhanced ability to enter dormancy. Biotechnology and Bioengineering 2020;117:3066-80. [DOI: 10.1002/bit.27479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
71 Dukaew N, Chairatvit K, Pitchakarn P, Imsumran A, Karinchai J, Tuntiwechapikul W, Wongnoppavich A. Inactivation of AKT/NF‑κB signaling by eurycomalactone decreases human NSCLC cell viability and improves the chemosensitivity to cisplatin. Oncol Rep 2020;44:1441-54. [PMID: 32945500 DOI: 10.3892/or.2020.7710] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Zhang J, Späth SS, Marjani SL, Zhang W, Pan X. Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment. Precis Clin Med 2018;1:29-48. [PMID: 30687561 DOI: 10.1093/pcmedi/pby007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 12.3] [Reference Citation Analysis]
73 Pramanik KC, Makena MR, Bhowmick K, Pandey MK. Advancement of NF-κB Signaling Pathway: A Novel Target in Pancreatic Cancer. Int J Mol Sci 2018;19:E3890. [PMID: 30563089 DOI: 10.3390/ijms19123890] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 14.7] [Reference Citation Analysis]
74 Kashyap D, Garg VK, Tuli HS, Yerer MB, Sak K, Sharma AK, Kumar M, Aggarwal V, Sandhu SS. Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential. Biomolecules 2019;9:E174. [PMID: 31064104 DOI: 10.3390/biom9050174] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 26.5] [Reference Citation Analysis]
75 Olmez I, Zhang Y, Manigat L, Benamar M, Brenneman B, Nakano I, Godlewski J, Bronisz A, Lee J, Abbas T, Abounader R, Purow B. Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 2018;78:4360-9. [PMID: 29844123 DOI: 10.1158/0008-5472.CAN-17-3124] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
76 Zhang LH, Yang AJ, Wang M, Liu W, Wang CY, Xie XF, Chen X, Dong JF, Li M. Enhanced autophagy reveals vulnerability of P-gp mediated epirubicin resistance in triple negative breast cancer cells. Apoptosis 2016;21:473-88. [PMID: 26767845 DOI: 10.1007/s10495-016-1214-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
77 Zhai Z, Samson JM, Yamauchi T, Vaddi PK, Matsumoto Y, Dinarello CA, Ravindran Menon D, Fujita M. Inflammasome Sensor NLRP1 Confers Acquired Drug Resistance to Temozolomide in Human Melanoma. Cancers (Basel) 2020;12:E2518. [PMID: 32899791 DOI: 10.3390/cancers12092518] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
78 Razaghi A, Heimann K, Schaeffer PM, Gibson SB. Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies. Apoptosis 2018;23:93-112. [PMID: 29322476 DOI: 10.1007/s10495-018-1440-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
79 Heavey S, Dowling P, Moore G, Barr MP, Kelly N, Maher SG, Cuffe S, Finn SP, O'Byrne KJ, Gately K. Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines. Sci Rep 2018;8:1652. [PMID: 29374181 DOI: 10.1038/s41598-018-19688-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
80 Pulito C, Cristaudo A, Porta C, Zapperi S, Blandino G, Morrone A, Strano S. Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res 2020;39:210. [PMID: 33028357 DOI: 10.1186/s13046-020-01715-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
81 Begalli F, Bennett J, Capece D, Verzella D, D'Andrea D, Tornatore L, Franzoso G. Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity. Biomedicines 2017;5:E50. [PMID: 28829404 DOI: 10.3390/biomedicines5030050] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
82 Mortezaee K, Salehi E, Mirtavoos-Mahyari H, Motevaseli E, Najafi M, Farhood B, Rosengren RJ, Sahebkar A. Mechanisms of apoptosis modulation by curcumin: Implications for cancer therapy. J Cell Physiol 2019;234:12537-50. [PMID: 30623450 DOI: 10.1002/jcp.28122] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 32.5] [Reference Citation Analysis]
83 Xia HW, Zhang ZQ, Yuan J, Niu QL. Human RECQL5 promotes metastasis and resistance to cisplatin in non-small cell lung cancer. Life Sci 2021;265:118768. [PMID: 33217443 DOI: 10.1016/j.lfs.2020.118768] [Reference Citation Analysis]
84 Thamilselvan V, Menon M, Stein GS, Valeriote F, Thamilselvan S. Combination of Carmustine and Selenite Inhibits EGFR Mediated Growth Signaling in Androgen-Independent Prostate Cancer Cells. J Cell Biochem 2017;118:4331-40. [PMID: 28430389 DOI: 10.1002/jcb.26086] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
85 Pogge von Strandmann E, Reinartz S, Wager U, Müller R. Tumor-Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure. Trends Cancer 2017;3:137-48. [PMID: 28718444 DOI: 10.1016/j.trecan.2016.12.005] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 13.0] [Reference Citation Analysis]
86 Ghoneum A, Said N. PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics. Cancers (Basel) 2019;11:E949. [PMID: 31284467 DOI: 10.3390/cancers11070949] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 18.5] [Reference Citation Analysis]
87 Yang L, Zhou Y, Li Y, Zhou J, Wu Y, Cui Y, Yang G, Hong Y. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells. Cancer Letters 2015;357:520-6. [DOI: 10.1016/j.canlet.2014.12.003] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 12.3] [Reference Citation Analysis]
88 Bravo-Cuellar A, Ortiz-Lazareno PC, Sierra-Díaz E, Solorzano-Ibarra F, Méndez-Clemente AS, Aguilar-Lemarroy A, Jave-Suárez LF, Ruiz Velazco-Niño É, Hernández-Flores G. Pentoxifylline Sensitizes Cisplatin-Resistant Human Cervical Cancer Cells to Cisplatin Treatment: Involvement of Mitochondrial and NF-Kappa B Pathways. Front Oncol 2020;10:592706. [PMID: 33680921 DOI: 10.3389/fonc.2020.592706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Shi L, Xu Z, Yang Q, Huang Y, Gong Y, Wang F, Ke B. IL-7-Mediated IL-7R-JAK3/STAT5 signalling pathway contributes to chemotherapeutic sensitivity in non-small-cell lung cancer. Cell Prolif 2019;52:e12699. [PMID: 31599032 DOI: 10.1111/cpr.12699] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
90 Gooding AJ, Parker KA, Valadkhan S, Schiemann WP. The IncRNA BORG: A novel inducer of TNBC metastasis, chemoresistance, and disease recurrence. J Cancer Metastasis Treat 2019;5:41. [PMID: 31435529 DOI: 10.20517/2394-4722.2019.11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
91 Gooding AJ, Zhang B, Gunawardane L, Beard A, Valadkhan S, Schiemann WP. The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers. Oncogene 2019;38:2020-41. [PMID: 30467380 DOI: 10.1038/s41388-018-0586-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 12.3] [Reference Citation Analysis]
92 Tilborghs S, Corthouts J, Verhoeven Y, Arias D, Rolfo C, Trinh XB, van Dam PA. The role of Nuclear Factor-kappa B signaling in human cervical cancer. Crit Rev Oncol Hematol 2017;120:141-50. [PMID: 29198328 DOI: 10.1016/j.critrevonc.2017.11.001] [Cited by in Crossref: 81] [Cited by in F6Publishing: 91] [Article Influence: 20.3] [Reference Citation Analysis]
93 Kumar N, Prasad P, Jash E, Saini M, Husain A, Goldman A, Sehrawat S. Insights into exchange factor directly activated by cAMP (EPAC) as potential target for cancer treatment. Mol Cell Biochem 2018;447:77-92. [PMID: 29417338 DOI: 10.1007/s11010-018-3294-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
94 Seo SH, Kim SG, Shin JH, Ham DW, Shin EH. Toxoplasma GRA16 Inhibits NF-κB Activation through PP2A-B55 Upregulation in Non-Small-Cell Lung Carcinoma Cells. Int J Mol Sci 2020;21:E6642. [PMID: 32927892 DOI: 10.3390/ijms21186642] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Wu JY, Weng YS, Chiou YC, Hsu FT, Chiang IT. Induction of Apoptosis and Inhibition of EGFR/NF-κB Signaling Are Associated With Regorafenib-sensitized Non-small Cell Lung Cancer to Cisplatin. In Vivo 2021;35:2569-76. [PMID: 34410944 DOI: 10.21873/invivo.12539] [Reference Citation Analysis]
96 Basu A, Upadhyay P, Ghosh A, Chattopadhyay D, Adhikary A. Folic-Acid-Adorned PEGylated Graphene Oxide Interferes with the Cell Migration of Triple Negative Breast Cancer Cell Line, MDAMB-231 by Targeting miR-21/PTEN Axis through NFκB. ACS Biomater Sci Eng 2019;5:373-89. [DOI: 10.1021/acsbiomaterials.8b01088] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
97 Bhootada Y, Choudhury S, Gully C, Gorbatyuk M. Targeting Caspase-12 to Preserve Vision in Mice With Inherited Retinal Degeneration. Invest Ophthalmol Vis Sci 2015;56:4725-33. [PMID: 26207309 DOI: 10.1167/iovs.15-16924] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
98 Zhu Y, Howard GA, Pittman K, Boykin C, Herring LE, Wilkerson EM, Verbanac K, Lu Q. Therapeutic Effect of Y-27632 on Tumorigenesis and Cisplatin-Induced Peripheral Sensory Loss through RhoA-NF-κB. Mol Cancer Res 2019;17:1910-9. [PMID: 31189689 DOI: 10.1158/1541-7786.MCR-19-0024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
99 Hammouda MB, Riahi-Chebbi I, Souid S, Othman H, Aloui Z, Srairi-Abid N, Karoui H, Gasmi A, Magnenat EM, Wells TNC, Clemetson KJ, Rodríguez-López JN, Essafi-Benkhadir K. Macrovipecetin, a C-type lectin from Macrovipera lebetina venom, inhibits proliferation migration and invasion of SK-MEL-28 human melanoma cells and enhances their sensitivity to cisplatin. Biochim Biophys Acta Gen Subj 2018;1862:600-14. [PMID: 29196192 DOI: 10.1016/j.bbagen.2017.11.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
100 Van Loenhout J, Peeters M, Bogaerts A, Smits E, Deben C. Oxidative Stress-Inducing Anticancer Therapies: Taking a Closer Look at Their Immunomodulating Effects. Antioxidants (Basel) 2020;9:E1188. [PMID: 33260826 DOI: 10.3390/antiox9121188] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
101 Kumar S, Oien DB, Khurana A, Cliby W, Hartmann L, Chien J, Shridhar V. Coiled-Coil and C2 Domain-Containing Protein 1A (CC2D1A) Promotes Chemotherapy Resistance in Ovarian Cancer. Front Oncol 2019;9:986. [PMID: 31632917 DOI: 10.3389/fonc.2019.00986] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
102 Ayyagari VN, Brard L. Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action. BMC Cancer 2014;14:61. [PMID: 24495391 DOI: 10.1186/1471-2407-14-61] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
103 Yin T, Zhang Z, Cao B, Duan Q, Shi P, Zhao H, Camara SN, Shen Q, Wang C. Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine. Oncotarget 2016;7:37192-204. [PMID: 27177084 DOI: 10.18632/oncotarget.9293] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
104 Chakraborty S, Mir KB, Seligson ND, Nayak D, Kumar R, Goswami A. Integration of EMT and cellular survival instincts in reprogramming of programmed cell death to anastasis. Cancer Metastasis Rev. 2020;. [PMID: 32020420 DOI: 10.1007/s10555-020-09866-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
105 Galinski B, Luxemburg M, Landesman Y, Pawel B, Johnson KJ, Master SR, Freeman KW, Loeb DM, Hébert JM, Weiser DA. XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB. Transl Oncol 2021;14:101114. [PMID: 33975179 DOI: 10.1016/j.tranon.2021.101114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Méndez-García LA, Nava-Castro KE, Ochoa-Mercado TL, Palacios-Arreola MI, Ruiz-Manzano RA, Segovia-Mendoza M, Solleiro-Villavicencio H, Cázarez-Martínez C, Morales-Montor J. Breast Cancer Metastasis: Are Cytokines Important Players During Its Development and Progression? J Interferon Cytokine Res 2019;39:39-55. [PMID: 30321090 DOI: 10.1089/jir.2018.0024] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
107 Kilic U, Sahin K, Tuzcu M, Basak N, Orhan C, Elibol-Can B, Kilic E, Sahin F, Kucuk O. Enhancement of Cisplatin sensitivity in human cervical cancer: epigallocatechin-3-gallate. Front Nutr 2014;1:28. [PMID: 25988128 DOI: 10.3389/fnut.2014.00028] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
108 Hsu FT, Chiang IT, Wang WS. Induction of apoptosis through extrinsic/intrinsic pathways and suppression of ERK/NF-κB signalling participate in anti-glioblastoma of imipramine. J Cell Mol Med 2020;24:3982-4000. [PMID: 32149465 DOI: 10.1111/jcmm.15022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
109 Robinson NJ, Miyagi M, Scarborough JA, Scott JG, Taylor DJ, Schiemann WP. SLX4IP promotes RAP1 SUMOylation by PIAS1 to coordinate telomere maintenance through NF-κB and Notch signaling. Sci Signal 2021;14:eabe9613. [PMID: 34187905 DOI: 10.1126/scisignal.abe9613] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Debreli Coskun M, Sudha T, Bharali DJ, Celikler S, Davis PJ, Mousa SA. αvβ3 Integrin Antagonists Enhance Chemotherapy Response in an Orthotopic Pancreatic Cancer Model. Front Pharmacol 2020;11:95. [PMID: 32174830 DOI: 10.3389/fphar.2020.00095] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
111 Zhu H, Gao J, Wang L, Qian KJ, Cai LP. In vitro study on reversal of ovarian cancer cell resistance to cisplatin by naringin via the nuclear factor-κB signaling pathway. Exp Ther Med 2018;15:2643-8. [PMID: 29456667 DOI: 10.3892/etm.2018.5695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
112 Thakur B, Ray P. Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-κB-TNFα-PIK3CA loop. J Exp Clin Cancer Res 2017;36:164. [PMID: 29169370 DOI: 10.1186/s13046-017-0636-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 9.0] [Reference Citation Analysis]
113 Carrà G, Torti D, Crivellaro S, Panuzzo C, Taulli R, Cilloni D, Guerrasio A, Saglio G, Morotti A. The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias. Oncotarget 2016;7:66287-98. [PMID: 27563822 DOI: 10.18632/oncotarget.11507] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
114 Eskandari Z, Bahadori F, Yenigun VB, Demiray M, Eroğlu MS, Kocyigit A, Oner ET. Levan enhanced the NF-κB suppression activity of an oral nano PLGA-curcumin formulation in breast cancer treatment. Int J Biol Macromol 2021;189:223-31. [PMID: 34419542 DOI: 10.1016/j.ijbiomac.2021.08.115] [Reference Citation Analysis]
115 Bram Ednersson S, Stenson M, Stern M, Enblad G, Fagman H, Nilsson-Ehle H, Hasselblom S, Andersson PO. Expression of ribosomal and actin network proteins and immunochemotherapy resistance in diffuse large B cell lymphoma patients. Br J Haematol 2018;181:770-81. [PMID: 29767447 DOI: 10.1111/bjh.15259] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
116 Pozdeyev N, Berlinberg A, Zhou Q, Wuensch K, Shibata H, Wood WM, Haugen BR. Targeting the NF-κB Pathway as a Combination Therapy for Advanced Thyroid Cancer. PLoS One 2015;10:e0134901. [PMID: 26263379 DOI: 10.1371/journal.pone.0134901] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
117 Mukherjee N, Houston TJ, Cardenas E, Ghosh R. To be an ally or an adversary in bladder cancer: the NF-κB story has not unfolded. Carcinogenesis 2015;36:299-306. [PMID: 25543121 DOI: 10.1093/carcin/bgu321] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
118 Elshimali YI, Wu Y, Khaddour H, Wu Y, Gradinaru D, Sukhija H, Chung SS, Vadgama JV. Optimization Of Cancer Treatment Through Overcoming Drug Resistance. J Cancer Res Oncobiol 2018;1:107. [PMID: 29932172 DOI: 10.31021/jcro.20181107] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
119 Wu J, Chen K, Zhang F, Jin J, Zhang N, Li D, Ying L, Chen W, Yu H, Mao W, Su D. Overcoming Linsitinib intrinsic resistance through inhibition of nuclear factor-κB signaling in esophageal squamous cell carcinoma. Cancer Med 2017;6:1353-61. [PMID: 28440057 DOI: 10.1002/cam4.1068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
120 Hasan M, Browne E, Guarinoni L, Darveau T, Hilton K, Witt-Enderby PA. Novel Melatonin, Estrogen, and Progesterone Hormone Therapy Demonstrates Anti-Cancer Actions in MCF-7 and MDA-MB-231 Breast Cancer Cells. Breast Cancer (Auckl) 2020;14:1178223420924634. [PMID: 32636633 DOI: 10.1177/1178223420924634] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
121 Song W, Tang Z, Shen N, Yu H, Jia Y, Zhang D, Jiang J, He C, Tian H, Chen X. Combining disulfiram and poly(l-glutamic acid)-cisplatin conjugates for combating cisplatin resistance. Journal of Controlled Release 2016;231:94-102. [DOI: 10.1016/j.jconrel.2016.02.039] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
122 Khattar E, Maung KZY, Chew CL, Ghosh A, Mok MMH, Lee P, Zhang J, Chor WHJ, Cildir G, Wang CQ, Mohd-Ismail NK, Chin DWL, Lee SC, Yang H, Shin YJ, Nam DH, Chen L, Kumar AP, Deng LW, Ikawa M, Gunaratne J, Osato M, Tergaonkar V. Rap1 regulates hematopoietic stem cell survival and affects oncogenesis and response to chemotherapy. Nat Commun 2019;10:5349. [PMID: 31836706 DOI: 10.1038/s41467-019-13082-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
123 Yamamoto K, Abe S, Honda A, Hashimoto J, Aizawa Y, Ishibashi S, Takemura T, Hanagata N, Yamamoto M, Miura O, Kurata M, Kitagawa M. Fatty acid beta oxidation enzyme HADHA is a novel potential therapeutic target in malignant lymphoma. Lab Invest 2020;100:353-62. [DOI: 10.1038/s41374-019-0318-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
124 Lewis T, Corcoran DB, Thurston DE, Giles PJ, Ashelford K, Walsby EJ, Fegan CD, Pepper AGS, Miraz Rahman K, Pepper C. Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers. Haematologica 2021;106:958-67. [PMID: 32381576 DOI: 10.3324/haematol.2019.238584] [Reference Citation Analysis]
125 Hwang HS, Park YY, Shin SJ, Go H, Park JM, Yoon SY, Lee JL, Cho YM. Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma. J Korean Med Sci 2020;35:e31. [PMID: 32030920 DOI: 10.3346/jkms.2020.35.e31] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
126 Zhang Y, Lu H, Xu G. [Effect of PI3K/AKT pathway on cisplatin resistance in non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2014;17:635-42. [PMID: 25130971 DOI: 10.3779/j.issn.1009-3419.2014.08.09] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
127 Khan MW, Zhao P, Khan A, Raza F, Raza SM, Sarfraz M, Chen Y, Li M, Yang T, Ma X, Xiang G. Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity. Int J Nanomedicine 2019;14:3753-71. [PMID: 31239661 DOI: 10.2147/IJN.S196651] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
128 Alves C, Serrano E, Silva J, Rodrigues C, Pinteus S, Gaspar H, Botana LM, Alpoim MC, Pedrosa R. Sphaerococcus coronopifolius bromoterpenes as potential cancer stem cell-targeting agents. Biomed Pharmacother 2020;128:110275. [PMID: 32480221 DOI: 10.1016/j.biopha.2020.110275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Kapur N, Mir H, Sonpavde GP, Jain S, Bae S, Lillard JW Jr, Singh S. Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel. Cancer Lett 2019;454:1-13. [PMID: 30974114 DOI: 10.1016/j.canlet.2019.04.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
130 Heavey S, O’byrne KJ, Gately K. Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treatment Reviews 2014;40:445-56. [DOI: 10.1016/j.ctrv.2013.08.006] [Cited by in Crossref: 80] [Cited by in F6Publishing: 85] [Article Influence: 11.4] [Reference Citation Analysis]
131 Ward AB, Mir H, Kapur N, Gales DN, Carriere PP, Singh S. Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways. World J Surg Oncol 2018;16:108. [PMID: 29898731 DOI: 10.1186/s12957-018-1400-z] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 16.0] [Reference Citation Analysis]
132 Chai JY, Sugumar V, Alshanon AF, Wong WF, Fung SY, Looi CY. Defining the Role of GLI/Hedgehog Signaling in Chemoresistance: Implications in Therapeutic Approaches. Cancers (Basel) 2021;13:4746. [PMID: 34638233 DOI: 10.3390/cancers13194746] [Reference Citation Analysis]
133 Wang A, Li J, Zhou T, Li T, Cai H, Shi H, Liu A. CUEDC2 Contributes to Cisplatin-Based Chemotherapy Resistance in Ovarian Serious Carcinoma by Regulating p38 MAPK Signaling. J Cancer 2019;10:1800-7. [PMID: 31205536 DOI: 10.7150/jca.29889] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
134 Vaghari-Tabari M, Majidinia M, Moein S, Qujeq D, Asemi Z, Alemi F, Mohamadzadeh R, Targhazeh N, Safa A, Yousefi B. MicroRNAs and colorectal cancer chemoresistance: New solution for old problem. Life Sci 2020;259:118255. [PMID: 32818543 DOI: 10.1016/j.lfs.2020.118255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
135 Vyse S, Howitt A, Huang PH. Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer. J Mol Biol 2017;429:1767-86. [PMID: 28478283 DOI: 10.1016/j.jmb.2017.04.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]